We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Hansa Biopharma AB (HNSA) NPV

Sell:49.84 SEK Buy:50.15 SEK Change: 1.63 SEK (3.19%)
Market closed |  Prices as at close on 12 July 2024 | Switch to live prices |
Sell:49.84 SEK
Buy:50.15 SEK
Change: 1.63 SEK (3.19%)
Market closed |  Prices as at close on 12 July 2024 | Switch to live prices |
Sell:49.84 SEK
Buy:50.15 SEK
Change: 1.63 SEK (3.19%)
Market closed |  Prices as at close on 12 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.

Contact details

Address:
Scheelevagen 22,
P.O. Box 785
LUND
220 07
Sweden
Telephone:
+46 (46) 165670
Website:
https://www.hansabiopharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
HNSA
ISIN:
SE0002148817
Market cap:
3.47 billion SEK
Shares in issue:
52.67 million
Sector:
Biotechnology
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Soeren Tulstrup
    President, Chief Executive Officer
  • Anne Lanner
    Chief Human Resource Officer, Senior Vice President
  • Hitto Kaufmann
    Senior Vice President, Chief Scientific Officer
  • Achim Kaufhold
    Senior Vice President, Chief Medical Officer
  • Matthew Shaulis
    Senior Vice President, Chief Commercial Officer and President, US

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.